TY - JOUR
T1 - Evidence-based guidelines for treatment of uterine body neoplasm in Japan
T2 - Japan Society of Gynecologic Oncology (JSGO) 2009 edition
AU - Nagase, Satoru
AU - Katabuchi, Hidetaka
AU - Hiura, Masamichi
AU - Sakuragi, Noriaki
AU - Aoki, Yoichi
AU - Kigawa, Junzo
AU - Saito, Tsuyoshi
AU - Hachisuga, Toru
AU - Ito, Kiyoshi
AU - Uno, Takashi
AU - Katsumata, Noriyuki
AU - Komiyama, Shinichi
AU - Susumu, Nobuyuki
AU - Emoto, Makoto
AU - Kobayashi, Hiroaki
AU - Metoki, Hirohito
AU - Konishi, Ikuo
AU - Ochiai, Kazunori
AU - Mikami, Mikio
AU - Sugiyama, Toru
AU - Mukai, Makio
AU - Sagae, Satoru
AU - Hoshiai, Hiroshi
AU - Aoki, Daisuke
AU - Ohmichi, Masahide
AU - Yoshikawa, Hiroyuki
AU - Iwasaka, Tsuyoshi
AU - Udagawa, Yasuhiro
AU - Yaegashi, Nobuo
N1 - Funding Information:
M. Mikami received a research funding from Mitsubishi Chemical Group Science and Technology Research Center, Inc., and N. Katsumata has received honoraria from Sanofi–aventis, Kyowa Hakko Kirin, Chugai Pharmaceutical, Yakult Honsha, Nippon Kayaku, and Ono Pharmaceutical. The other authors have no conflict of interest.
PY - 2010/12
Y1 - 2010/12
N2 - Endometrial carcinoma is one of the most common gynecologic malignancies in Japan and its incidence has increased recently. Although surgery is the cornerstone of the management of patients with endometrial cancer, there is significant variation in Japan with regard to the type of hysterectomy employed. Additionally, it remains controversial whether full nodal staging is required in all patients. Furthermore, adjuvant therapy differs between Japan and Western countries. To delineate clearly the standard of care for endometrial cancer treatment in Japan, the guidelines for the treatment of endometrial cancer were published in 2006 and revised in 2009. The 2009 edition included topics not addressed in the previous edition including the treatment of mesenchymal tumors, for example leiomyosarcoma, and sections covering the treatment of serous and clear-cell adenocarcinoma. These guidelines are composed of nine chapters and include nine algorithms. The guidelines also contain fifty-one clinical questions (CQs) and each CQ consists of recommendations, background, explanations, and references. The treatment recommendations herein are tailored to reflect current Japanese clinical practice and ensure equitable care for all Japanese women diagnosed with endometrial cancer.
AB - Endometrial carcinoma is one of the most common gynecologic malignancies in Japan and its incidence has increased recently. Although surgery is the cornerstone of the management of patients with endometrial cancer, there is significant variation in Japan with regard to the type of hysterectomy employed. Additionally, it remains controversial whether full nodal staging is required in all patients. Furthermore, adjuvant therapy differs between Japan and Western countries. To delineate clearly the standard of care for endometrial cancer treatment in Japan, the guidelines for the treatment of endometrial cancer were published in 2006 and revised in 2009. The 2009 edition included topics not addressed in the previous edition including the treatment of mesenchymal tumors, for example leiomyosarcoma, and sections covering the treatment of serous and clear-cell adenocarcinoma. These guidelines are composed of nine chapters and include nine algorithms. The guidelines also contain fifty-one clinical questions (CQs) and each CQ consists of recommendations, background, explanations, and references. The treatment recommendations herein are tailored to reflect current Japanese clinical practice and ensure equitable care for all Japanese women diagnosed with endometrial cancer.
KW - Chemotherapy
KW - Clinical practice guidelines
KW - Endometrial cancer
KW - Irradiation
KW - Surgery
UR - http://www.scopus.com/inward/record.url?scp=78651060615&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78651060615&partnerID=8YFLogxK
U2 - 10.1007/s10147-010-0138-6
DO - 10.1007/s10147-010-0138-6
M3 - Article
C2 - 21069552
AN - SCOPUS:78651060615
SN - 1341-9625
VL - 15
SP - 531
EP - 542
JO - International Journal of Clinical Oncology
JF - International Journal of Clinical Oncology
IS - 6
ER -